

References

1. Day SJ and Altman DG. Blinding in clinical trials and other studies. *BMJ*. 2000;321:504.
2. Higgins JPT and Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
3. Sakamoto Y, Ebihara S, Ebihara T, Tomita N, Toba K, Freeman S, Arai H and Kohzuki M. Fall prevention using olfactory stimulation with lavender odor in elderly nursing home residents: a randomized controlled trial. *J Am Geriatr Soc*. 2012;60:1005-11.
4. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA and Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. *J Clin Epidemiol*. 2002;55:787-90.
5. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M and Guyatt GH. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. *JAMA*. 2001;285:2000-3.
6. Schulz KF, Altman DG and Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340.
7. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M and Altman DG. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340.
8. Karanicolas PJ, Farrokhyar F and Bhandari M. Blinding: Who, what, when, why, how? *Canadian Journal of Surgery*. 2010;53:345-348.
9. Schulz KF, Chalmers I, Hayes RJ and Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA*. 1995;273:408-12.
10. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C and Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. *JAMA*. 2002;287:2973-82.